Affinity Asset Advisors LLC Purchases 213,733 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY)

Affinity Asset Advisors LLC increased its position in Inozyme Pharma, Inc. (NASDAQ:INZY) by 8.1% in the second quarter, Holdings Channel.com reports. The fund owned 2,856,252 shares of the company’s stock after purchasing an additional 213,733 shares during the period. Inozyme Pharma makes up about 1.5% of Affinity Asset Advisors LLC’s investment portfolio, making the stock its 18th largest position. Affinity Asset Advisors LLC’s holdings in Inozyme Pharma were worth $12,739,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in INZY. Superstring Capital Management LP bought a new stake in shares of Inozyme Pharma in the fourth quarter worth approximately $528,000. Values First Advisors Inc. bought a new stake in shares of Inozyme Pharma during the 2nd quarter valued at about $76,000. Samlyn Capital LLC lifted its stake in shares of Inozyme Pharma by 15.0% in the 2nd quarter. Samlyn Capital LLC now owns 3,350,535 shares of the company’s stock worth $14,943,000 after purchasing an additional 437,622 shares during the period. Eventide Asset Management LLC grew its position in Inozyme Pharma by 1.8% during the fourth quarter. Eventide Asset Management LLC now owns 3,179,837 shares of the company’s stock valued at $13,546,000 after buying an additional 54,837 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of Inozyme Pharma by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 2,419,020 shares of the company’s stock worth $18,530,000 after acquiring an additional 33,998 shares during the last quarter. 88.30% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. HC Wainwright restated a “buy” rating and set a $14.00 target price on shares of Inozyme Pharma in a research note on Thursday, August 8th. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price target on shares of Inozyme Pharma in a research note on Tuesday, August 6th. Stifel Nicolaus assumed coverage on Inozyme Pharma in a research report on Thursday, September 12th. They issued a “buy” rating and a $16.00 target price on the stock. Jefferies Financial Group reaffirmed a “buy” rating and set a $17.00 price target (up from $16.00) on shares of Inozyme Pharma in a research note on Tuesday, August 13th. Finally, Wedbush restated an “outperform” rating and set a $15.00 target price on shares of Inozyme Pharma in a research report on Tuesday, August 6th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $16.14.

Inozyme Pharma Stock Down 0.4 %

Shares of NASDAQ:INZY opened at $5.23 on Wednesday. Inozyme Pharma, Inc. has a 1 year low of $2.69 and a 1 year high of $7.80. The company has a quick ratio of 9.84, a current ratio of 9.84 and a debt-to-equity ratio of 0.48. The business’s 50-day moving average is $5.28 and its 200 day moving average is $5.14.

Inozyme Pharma (NASDAQ:INZY) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.07). On average, analysts anticipate that Inozyme Pharma, Inc. will post -1.68 earnings per share for the current fiscal year.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.